Aug 12, 2024, 6:50 PM
Aug 12, 2024, 6:50 PM

Social Security Expands Benefits for More Health Conditions

Highlights
  • Social Security Administration adds 9 new health conditions to expedited benefits program.
  • Compassionate Allowances program now covers 287 conditions, including cancers and brain disorders.
  • These changes aim to provide faster support to individuals with severe health conditions.
Story

The Social Security Administration (SSA) has announced the addition of nine new health conditions to its Compassionate Allowances program, which expedites access to disability benefits for individuals with severe medical issues. This initiative aims to streamline the application process for those suffering from both rare and more common conditions, ensuring they receive timely support. Among the newly included conditions are several serious health issues, such as a rare genetic disorder that leads to developmental delays, heart complications, and short stature. Other notable additions include Adult Heart Transplant Wait List status levels, Histiocytic Malignancies, and Neonatal Marfan Syndrome. The SSA has also updated two existing conditions on the list, enhancing the program's responsiveness to evolving medical knowledge. Histiocytosis, a term encompassing various syndromes characterized by an abnormal increase in histiocytes—white blood cells that can cause tissue damage or tumors—has been highlighted in the revisions. Since the program's inception in 2008, the number of qualifying conditions has grown from 50, reflecting the SSA's commitment to addressing the needs of individuals with debilitating health issues. The public is encouraged to propose additional conditions for consideration, reinforcing the collaborative nature of the Compassionate Allowances program. As stated by SSA officials, “Compassionate Allowances helps in this effort by accelerating the disability application process for people who are likely to get approved for benefits due to the severity of their medical condition.”

Opinions

You've reached the end